In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01)
Studies comparing different doses and formulations have shown that more gastrointestinal side effects are experienced in the first few weeks of treatment
Choose minimally processed foods
Learn about the common side effects such as nausea, headache, dizziness, and vomiting, as well as rare but serious warning signs like blurred vision, sudden loss of vision in one eye, severe abdominal pain, and jaundice
Up to 40% of total weight lost on GLP-1 drugs is lean mass (muscle), not fat